Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | S100B | P04271 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | RARA | P10276 | 3/20 | 0.38 |
| ▸ | RARB | P10826 | 3/20 | 0.38 |
| ▸ | RARG | P13631 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382856 | 0.98 | RBP4 (0.58) | RBP4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL16244952 | 0.85 | RBP4 (0.59) | RBP4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL3722060 | 0.83 | RBP4 (0.54) | RBP4MAPTMEN1KMT2AGAA | |
| SCHEMBL13277642 | 0.83 | RBP4 (0.54) | RBP4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14852457 | 0.83 | RBP4 (0.54) | RBP4HTT | |
| Hydrochloric Acid SCHEMBL631208 | 0.82 | RBP4 (0.53) | RBP4MAPTLMNAHTT | |
| SCHEMBL15726858 | 0.81 | ALDH1A1 (0.45) | RBP4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14200003 | 0.81 | CYP2C9 (0.41) | RBP4ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL382564 | 0.81 | NOTUM (0.51) | RBP4 | |
| SCHEMBL766289 | 0.79 | RBP4 (0.74) | RBP4ALDH1A1MAPTGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946446-B2 | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-γ (ROR-γ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases | PHENEX PHARMACEUTICALS AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2014-05-22 | — | — | US | disclosed |
| EP-2697197-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | Phenex Pharmaceuticals AG (DE) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012139775-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | PHENEX PHARMACEUTICALS AG (DE) | 2012-10-18 | — | — | WO | disclosed |
| US-8163952-B2 | RAR receptor agonist ligands and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2146951-B1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100261754-A1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2146951-A2 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008152260-A2 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261754-A1 | NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | RARA, RARB, RARG | RBP4 99/4885ALDH1A1 199/4885MAPT 4686/4885 |
| US-20140142082-A1 | PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES | RORA, RORB, RORC | RBP4 150/4885ALDH1A1 1897/4885MAPT 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.